RxDoctor Payments Data

Rose Ngishu, MD

Internal Medicine · Benbrook, TXNPI 1063809531

Payments from drug & device makers

$2,327in general payments, 2019–2025

Across 127 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$323
  • Novo Nordisk$319
  • Pfizer$271
  • AstraZeneca$238
  • Amgen$157
  • Astellas Pharma US Inc$146
  • plus $873 from 15 others

What the payments were for

  • Food & beverage$2,24596%
  • Education$834%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,327 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,241
Medicare patients
71
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$20,347
FarxigaDapagliflozin Propanediol14$17,727
JardianceEmpagliflozin13$17,109
OzempicSemaglutide16$16,940
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,656
Gabapentin62$914
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$765
Atorvastatin Calcium75$757
Albuterol Sulfate HfaAlbuterol Sulfate36$718
Potassium Chloride38$654
Omeprazole25$625
Losartan Potassium46$493
Levothyroxine Sodium47$459
Pantoprazole Sodium28$431
Amlodipine Besylate54$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$323$20,34717 claims
AstraZenecaFarxiga$238$17,72714 claims
Boehringer IngelheimJardiance$142$17,10913 claims
Novo NordiskOzempic$319$16,94016 claims
GSKTrelegy Ellipta$126$13,65615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Benbrook

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →